HBV Genotype BC and Response to Lamivudine Therapy: A Systematic Review

Abstract EN

A number of nucleoside analogues such as lamivudine (LAM), actually used for the treatment of chronic hepatitis B, can suppress HBV DNA replication, improve transaminase level and liver histology, and enhance the rate of hepatitis B e antigen (HBeAg) clearance.

The responses to LAM therapy involve HBeAg clearance and HBV DNA conversion of negative.

However, the associations between HBV genotype B/C and response to LAM therapy remain ambiguous.

The aim of this meta-analysis is to determine more precise estimations of the relationship.

All the publications on the associations between HBV genotype B/C and response to LAM (HBeAg clearance and HBV DNA conversion of negative) through June 2013 were collected.

Relative risk (RR) with 95% confidence intervals (95% CI) was calculated in fixed or random model, I2 was calculated to examine heterogeneity, and funnel plots were plotted to examine small study effects with Stata 11 software.

Overall, for HBeAg clearance and genotype B/C, the RR (95% CI) was 1.27 (0.94–1.71), while for HBV DNA conversion of negative and genotype B/C, the RR (95% CI) was 1.07 (0.98–1.17).

HBV genotype B/C shows no significance associations with response to lamivudine therapy (HBeAg clearance and HBV DNA conversion of negative).